scholarly article | Q13442814 |
P2093 | author name string | Lidia Nagae | |
Justin M Honce | |||
Eric Nyberg | |||
P2860 | cites work | Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy | Q24683776 |
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis | Q84038259 | ||
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy | Q84114256 | ||
Melanoma complicating treatment with natalizumab (tysabri) for multiple sclerosis | Q84243572 | ||
Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients | Q84337909 | ||
Natalizumab and central nervous system lymphoma: no clear association | Q84617830 | ||
Another complication of natalizumab treatment? Taking the challenge | Q84617833 | ||
Natalizumab risk stratification: role of a two- step anti-JCV antibody assay | Q84894409 | ||
Natalizumab dosage suspension: are we helping or hurting? | Q84984557 | ||
Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy | Q85180313 | ||
PML in a patient treated with fumaric acid | Q86649822 | ||
PML in a patient treated with dimethyl fumarate from a compounding pharmacy | Q86649825 | ||
PML in a patient without severe lymphocytopenia receiving dimethyl fumarate | Q87077624 | ||
Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true? | Q87127669 | ||
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy | Q87474221 | ||
Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients | Q87673522 | ||
Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab | Q26851341 | ||
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring | Q28243804 | ||
Progressive multifocal leukoencephalopathy in a patient treated with natalizumab | Q28255536 | ||
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis | Q28255548 | ||
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease | Q28255557 | ||
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis | Q29616119 | ||
MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain | Q30049081 | ||
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. | Q30583907 | ||
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 | ||
The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy | Q30689194 | ||
Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. | Q30802654 | ||
Neuroimaging in posterior reversible encephalopathy syndrome | Q30923275 | ||
Seizures and their outcome in progressive multifocal leukoencephalopathy | Q31030491 | ||
Progressive multifocal leukoencephalopathy: value of diffusion-weighted and contrast-enhanced magnetic resonance imaging for diagnosis and treatment control | Q31050655 | ||
Natalizumab | Q31081472 | ||
Neuro MR: principles. | Q31121249 | ||
Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual | Q33193190 | ||
Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study | Q33443670 | ||
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study | Q33571905 | ||
Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons | Q33834119 | ||
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis | Q33893285 | ||
Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis | Q34089586 | ||
Progressive multifocal leukoencephalopathy: why gray and white matter | Q34307762 | ||
Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy | Q34324861 | ||
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients | Q34562841 | ||
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. | Q34621839 | ||
Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy | Q34629205 | ||
Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. | Q34803324 | ||
Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy | Q34993076 | ||
Immune reconstitution inflammatory syndrome in natalizumab-associated PML. | Q35215625 | ||
Proton magnetic resonance spectroscopy pattern of progressive multifocal leukoencephalopathy in AIDS. | Q35450600 | ||
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. | Q35609239 | ||
JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. | Q35870644 | ||
Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? | Q36544721 | ||
MRI aspects of progressive multifocal leukoencephalopathy | Q36669261 | ||
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab. | Q37035618 | ||
Getting specific: monoclonal antibodies in multiple sclerosis. | Q37165875 | ||
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function | Q37180600 | ||
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients | Q37206687 | ||
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases | Q37714089 | ||
Fingolimod after natalizumab and the risk of short-term relapse | Q37725909 | ||
Imaging manifestations of progressive multifocal leukoencephalopathy | Q37745226 | ||
Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients | Q41069030 | ||
Persistence of DNA Sequences of BK Virus and JC Virus in Normal Human Tissues and in Diseased Tissues | Q41555932 | ||
MRI pattern in asymptomatic natalizumab-associated PML. | Q41745436 | ||
Progressive multifocal leukoencephalopathy with selective involvement of the pyramidal tracts | Q42165687 | ||
Progressive Multifocal Leukoencephalopathy in AIDS: Proton MR Spectroscopy Patterns of Asynchronous Lesions Confirmed by Serial Diffusion-Weighted Imaging and Apparent Diffusion Coefficient Mapping | Q42769448 | ||
Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients | Q43720340 | ||
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study | Q43765361 | ||
Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation? | Q43897444 | ||
What to expect after natalizumab cessation in a real-life setting | Q44012129 | ||
Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations. | Q44045441 | ||
Progressive multifocal leukoencephalopathy with gray matter involvement | Q44132348 | ||
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies | Q44417521 | ||
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis | Q44825022 | ||
Allergic and nonallergic delayed infusion reactions during natalizumab therapy | Q46599353 | ||
Melanoma complicating treatment with natalizumab for multiple sclerosis | Q46767631 | ||
Progressive multifocal leukoencephalopathy: analysis of lesion development with diffusion-weighted MRI. | Q48216499 | ||
Progressive multifocal leukoencephalopathy: serial high-b-value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy. | Q48274489 | ||
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod | Q48319736 | ||
Diagnosis of progressive multifocal leukoencephalopathy by computed tomography | Q48329153 | ||
Tumefactive multiple sclerosis lesions under fingolimod treatment | Q48350609 | ||
The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas? | Q48401612 | ||
Primary central nervous system lymphoma in a patient treated with natalizumab | Q48444344 | ||
Reduced diffusion in a subset of acute MS lesions: a serial multiparametric MRI study | Q48519323 | ||
Massive exacerbation of multiple sclerosis after withdrawal and early restart of treatment with natalizumab | Q48588720 | ||
Progressive multifocal leukoencephalopathy limited to the brain stem | Q48635790 | ||
Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy | Q48745765 | ||
Lesion extension detected by diffusion-weighted magnetic resonance imaging in progressive multifocal leukoencephalopathy | Q48749920 | ||
MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. | Q48829236 | ||
Progressive multifocal leukoencephalopathy: its pathological features | Q48846642 | ||
Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report. | Q50802394 | ||
Herpes encephalitis during natalizumab treatment in multiple sclerosis. | Q50984779 | ||
Central nervous system lymphoma associated with natalizumab. | Q54390890 | ||
Acute disseminated encephalomyelitis | Q56038008 | ||
Progressive multifocal leukoencephalopathy | Q57112346 | ||
Primary central nervous system lymphoma in a patient treated with Natalizumab | Q57580323 | ||
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report | Q61657746 | ||
Lethal multiple sclerosis relapse after natalizumab withdrawal | Q61709468 | ||
Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence? | Q61718801 | ||
AIDS- and non-AIDS-related PML association with distinct p53 polymorphism | Q73461654 | ||
Progressive multifocal leukoencephalopathy | Q73551630 | ||
Conventional and diffusion-weighted MRI in progressive multifocal leukoencephalopathy: new elements for identification and follow-up | Q79190198 | ||
Diffusion-weighted imaging in patients with progressive multifocal leukoencephalopathy | Q80831430 | ||
MRI in PML: bilateral medullary lesions | Q81208763 | ||
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients | Q81301426 | ||
Infratentorial progressive multifocal leucoencephalopathy (PML) in a patient with SLE (2008: 4b) | Q81472465 | ||
More on melanoma with transdifferentiation | Q81568029 | ||
Natalizumab discontinuation: an increasingly tricky proposition | Q82349582 | ||
Severe acute autoimmune hepatitis after natalizumab treatment | Q82877307 | ||
Clinically significant liver injury in patients treated with natalizumab | Q82935643 | ||
Value of MRI as a surrogate marker for PML in natalizumab long-term therapy | Q83363676 | ||
Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance | Q83389204 | ||
Natalizumab-associated central nervous system lymphoma?--another patient | Q83555059 | ||
P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | neuroimaging | Q551875 |
multiple sclerosis | Q8277 | ||
P304 | page(s) | 809252 | |
P577 | publication date | 2015-01-01 | |
P1433 | published in | Multiple Sclerosis International | Q26853855 |
P1476 | title | Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities | |
P478 | volume | 2015 |